echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > 2022 ESMO| Professor Zhang Pin: Update of follow-up data from the DAWNA-1 study for sustained benefit and reliability in patients with HR+/HER2-advanced breast cancer

    2022 ESMO| Professor Zhang Pin: Update of follow-up data from the DAWNA-1 study for sustained benefit and reliability in patients with HR+/HER2-advanced breast cancer

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    With longer follow-up, darcily plus fulvestrant benefits are long-lasting and adverse reactions are manageable and manageable




    The highly anticipated European Society of Oncology (ESMO) congress kicked off


  • In clinical practice, for patients with concomitant visceral metastases, Chinese doctors are more likely to choose chemotherapy regimens for treatment


  • The security characteristics are consistent with the past,

    Single adverse reaction, better liver safety



    Vice Chairman of the Internal Medicine Professional Committee of the Beijing Society for the Prevention and Treatment of Breast Diseases

    Vice Chairman of the Breast Cancer Branch Committee of the Chinese Gerontological Society

    Vice Chairman of breast disease branch of Beijing Medical Association

    Member of the Standing Committee of the Breast Disease Training Expert Committee of the Chinese Medical Doctor Association

    Member of the Standing Committee of the Clinical Oncology Expert Committee of the Chinese Association of Women Physicians

    Member of the Standing Committee of the Breast Professional Committee of the Chinese Association of Research Hospitals

    Member of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association

    Member of the Tumor Clinical Chemotherapy Professional Committee of the Chinese Anti-Cancer Association

    Member of breast disease expert committee of Beijing Medical Doctor Association

    References:

    [1] Pin Zhang, Qingyuan Zhang, Xichun H, et al.


    [2] Xu B, Zhang Q, Zhang P, et al.







    Click "Read the original article" for more information

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.